Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGXXNASDAQ:CDXCNASDAQ:MNMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21753,536 shs554,788 shsMNMDMind Medicine (MindMed)$6.45+4.9%$6.12$4.70▼$10.44$486.12M2.521.38 million shs724,349 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGXXBright Green0.00%0.00%0.00%+50.00%-71.68%CDXCChromaDex0.00%0.00%0.00%+43.00%+129.97%MNMDMind Medicine (MindMed)+4.71%-1.53%+18.78%-21.63%-30.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/ACDXCChromaDex2.9047 of 5 stars3.50.00.04.00.00.01.9MNMDMind Medicine (MindMed)2.2792 of 5 stars3.63.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGXXBright Green 0.00N/AN/AN/ACDXCChromaDex 3.00Buy$9.03∞ UpsideMNMDMind Medicine (MindMed) 3.23Buy$25.11289.32% UpsideCurrent Analyst Ratings BreakdownLatest CDXC, BGXX, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/17/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/10/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.003/7/2025MNMDMind Medicine (MindMed)Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$27.00 ➝ $16.003/7/2025MNMDMind Medicine (MindMed)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.003/5/2025CDXCChromaDexLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.80 ➝ $8.10(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/ACDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/ACDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/AMNMDMind Medicine (MindMed)-$95.73M-$1.29N/AN/AN/AN/A-47.56%-35.55%N/ALatest CDXC, BGXX, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A3/6/2025Q4 2024MNMDMind Medicine (MindMed)-$0.33-$0.41-$0.08-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGXXBright GreenN/AN/AN/AN/AN/ACDXCChromaDexN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGXXBright GreenN/A0.010.01CDXCChromaDexN/A2.952.35MNMDMind Medicine (MindMed)0.099.009.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGXXBright Green7.83%CDXCChromaDex15.41%MNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipBGXXBright Green62.55%CDXCChromaDex9.64%MNMDMind Medicine (MindMed)2.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGXXBright Green2191.17 million71.59 millionNo DataCDXCChromaDex12077.75 million69.02 millionOptionableMNMDMind Medicine (MindMed)4075.37 million71.68 millionOptionableCDXC, BGXX, and MNMD HeadlinesRecent News About These CompaniesWhy Mind Medicine (MindMed) Inc.’s (MNMD) Stock Is Up 5.37%May 12 at 9:54 PM | aaii.comMind Medicine (MindMed) (NASDAQ:MNMD) Receives Buy Rating from Chardan CapitalMay 12 at 3:27 AM | americanbankingnews.comChardan Capital Reaffirms "Buy" Rating for Mind Medicine (MindMed) (NASDAQ:MNMD)May 11 at 8:43 AM | marketbeat.comDriehaus Capital Management LLC Cuts Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 11 at 6:50 AM | marketbeat.comEarnings call transcript: MindMed Q1 2025 results show mixed signalsMay 10 at 2:54 AM | uk.investing.comDeep Track Capital LP Has $19.60 Million Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 9, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comMindMed Reports First Quarter 2025 Financial Results and Recent Business UpdatesMay 8, 2025 | businesswire.comBlackstone Inc. Trims Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 8, 2025 | marketbeat.comMind Medicine Q1 2025 Earnings PreviewMay 7, 2025 | msn.comAllostery Investments LP Invests $905,000 in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 4, 2025 | marketbeat.comAlly Bridge Group NY LLC Sells 458,233 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)May 4, 2025 | marketbeat.comMind Medicine (MindMed) (MNMD) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comTri Locum Partners LP Decreases Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)April 29, 2025 | marketbeat.comMindMed to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | businesswire.comInstitutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)April 24, 2025 | finance.yahoo.comMarshall Wace LLP Purchases 213,526 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)April 23, 2025 | marketbeat.comGeode Capital Management LLC Acquires 45,386 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)April 23, 2025 | marketbeat.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Rating of "Buy" by AnalystsApril 21, 2025 | marketbeat.comQ1 Earnings Estimate for MNMD Issued By Leerink PartnrsApril 18, 2025 | marketbeat.comMindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)April 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXC, BGXX, and MNMD Company DescriptionsBright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.ChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Mind Medicine (MindMed) NASDAQ:MNMD$6.45 +0.30 (+4.88%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$6.34 -0.12 (-1.78%) As of 05/12/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
